

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 August 2022 (18.08.2022)



(10) International Publication Number
WO 2022/174031 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) C07D 207/30 (2006.01)
A61K 31/40 (2006.01)

(21) International Application Number:

PCT/US2022/016114

(22) International Filing Date:

11 February 2022 (11.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/149,095	12 February 2021 (12.02.2021)	US
63/166,638	26 March 2021 (26.03.2021)	US
63/192,627	25 May 2021 (25.05.2021)	US
63/250,473	30 September 2021 (30.09.2021)	US
63/292,337	21 December 2021 (21.12.2021)	US

(71) Applicant: **RELAY THERAPEUTICS, INC.** [US/US];
399 Binney St., 2nd Floor, Cambridge, Massachusetts
02139 (US).

(72) Inventors: **TAYLOR, Alexander M.**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **BRIGGS, Timothy F.**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **PABON, Nicolas A.**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **HE, Jing**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **LESCARBEAU, Andre**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **BOEZIO, Alessandro**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **EVANS, Catherine A.**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **FRIDRICH, Cary Griffin**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **KELLEY, Brian P.**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **KRUEGER, Elaine B.**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **KURUKU-LASURIYA, Ravi**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US). **MCLEAN, Thomas H.**; c/o Relay Therapeutics, Inc., 399 Binney St., 2nd Floor, Cambridge, Massachusetts 02139 (US).

(74) Agent: **PACE, Nicholas J.** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: CDK INHIBITORS AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of CDK enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with CDK signaling with the compounds and compositions of the disclosure.



WO 2022/174031 A1